FBRX trades 204.9% below Wall Street's consensus target of $65.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FBRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, Forte Biosciences, Inc. (FBRX) has a Wall Street consensus price target of $65.00, based on estimates from 6 covering analysts. With the stock currently trading at $21.32, this represents a potential upside of +204.9%. The company has a market capitalization of $3.80B.
Analyst price targets range from a low of $65.00 to a high of $65.00, representing a 0% spread in expectations. The median target of $65.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FBRX trades at a trailing P/E of -4.5x. Analysts expect EPS to grow -865.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ETONEton Pharmaceuticals, Inc. | $1.0B | $36.73 | $57.00 | +55.2% | Buy | 45.8x | 6 |
PRAXPraxis Precision Medicines, Inc. | $10.1B | $350.06 | $584.00 | +66.8% | Buy | — | 16 |
SLDBSolid Biosciences Inc. | $738M | $9.47 | $17.00 | +79.5% | Buy | — | 21 |
TARSTarsus Pharmaceuticals, Inc. | $2.6B | $61.26 | $68.00 | +11.0% | Buy | — | 9 |
NUVLNuvalent, Inc. | $9.1B | $123.51 | $127.32 | +3.1% | Hold | — | 18 |
DERMJourney Medical Corporation | $187M | $6.79 | $11.75 | +73.0% | Buy | 104.5x | 3 |
ACLXArcellx, Inc. | $6.7B | $115.07 | $112.45 | -2.3% | Hold | — | 18 |
RCKTRocket Pharmaceuticals, Inc. | $368M | $3.37 | $5.00 | +48.4% | Buy | — | 19 |
KRYSKrystal Biotech, Inc. | $11.1B | $378.15 | $336.40 | -11.0% | Buy | 49.3x | 17 |
ABBVAbbVie Inc. | $449.3B | $254.31 | $258.00 | +1.5% | Buy | 17.9x | 41 |
Quick answers to the most common questions about buying FBRX stock.
The consensus Wall Street price target for FBRX is $65, representing 204.9% upside from the current price of $21.32. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
FBRX has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $65 implies 204.9% upside from current levels.
FBRX's current price is $21.32 with a consensus target of $65 (204.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $65 for FBRX, while the most conservative target is $65. The consensus of $65 represents the median expectation. These targets typically reflect 12-month expectations.
FBRX is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FBRX stock forecast based on 6 Wall Street analysts shows a consensus price target of $65, with estimates ranging from $65 (bear case) to $65 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on FBRX, with a "Buy" consensus rating and $65 price target (204.9% upside). 3 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FBRX analyst price targets range from $65 to $65, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $65 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.